We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen’s SGLT-2 Diabetes Drug Gets Tentative Thumbs Up From FDA Panel
Janssen’s SGLT-2 Diabetes Drug Gets Tentative Thumbs Up From FDA Panel
January 11, 2013
A panel of FDA advisers voted to recommend approval of Janssen Pharmaceuticals’ Type 2 diabetes drug canagliflozin, saying the drug’s apparent cardiovascular risks (CV) were likely a product of incomplete safety data and could be allayed by long-term postmarket studies.